Companies in #Solid tumors
Found 2 companies operating in this sector.
Clinical-stage biopharmaceutical company (NASDAQ: CNTX) advancing medicines for solid tumors, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody. In August 2026 the company discontinued its bispecific program to extend its cash runway into 2027.
Commercial-stage biopharmaceutical company (NASDAQ: IOVA) developing and commercializing autologous tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its lead product Amtagvi (lifileucel) is an individualized T cell therapy approved for previously treated advanced or unresectable or metastatic melanoma, marketed alongside Proleukin (interleukin-2). The pipeline extends lifileucel into cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma, with next-generation programs including LN-145, IOV-2001, IOV-4001, and IOV-3001. Q2 2026 product revenue of $99.3 million (up from $59 million a year earlier) powered a roughly 43% single-day gain and a new 52-week high in August 2026.